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APPENDIX. CONFERENCE DISCUSSION
Dr N. Bonaros (Innsbruck, Austria): This is a solidly designed study with good
statistical methods and good results. I have a comment and a question.
Five out of six observational studies included in this report were performed
in an era before the introduction of the SYNTAX score as an assessment param-
eter of the complexity of coronary lesions; thus, in 1588 out of 2885 patients,
the decision for stratiﬁcation to MIDCAB or PCI was mainly based on the feasi-
bility of performing PCI or not. This leads us to the suspicion that easy PCI
targets, which we would now call low SYNTAX score targets, were treated with
PCI and thus were included in the PCI group, while difﬁcult PCI targets, now
called high SYNTAX score lesions, were treated by surgical revascularization.
With this in mind, do you think that this meta-analysis should include both pro-
spective randomized and observational data?
And my comment: in your abstract conclusions you state that this
meta-analysis underscores the superiority of MIDCAB over PCI for the treat-
ment of single-vessel disease. Similar to the one-year results of the SYNTAX
trial, surgical revascularization has proven to be superior in terms of MACCE.
Do you still think that?
Dr Deppe: Regarding your question, it is correct that most of the studies in
our meta-analysis were published before the SYNTAX score was established
and therefore this tool was not available. I’m not sure if I completely under-
stood your comment, but I still believe in the superiority of the mammary
artery compared with PCI and stenting and our data suggest that you should
revascularize the left anterior descending artery with a graft surgically.
Dr S. Head (Rotterdam, Netherlands): If I may comment on the last question.
The SYNTAX score actually is applicable to patients with 3-vessel disease or
left main disease. So in patients with isolated LAD it may not be the most
appropriate score to guide the decision-making between patients that
undergo PCI or CABG. Of course, as you said, there may be some differences
in observational studies as to which patients underwent PCI and which
patients underwent CABG. But the SYNTAX score doesn’t translate to these
patients. It’s only validated in patients with 3-vessel or left main disease, and
therefore we’re not so sure whether it would actually work in isolated LAD as
well.
Dr Bonaros: I think the SYNTAX score is, of course, a good tool. The thing is
that the decision-making back then in the observational studies was based on
the complexity of the lesion. So I don’t think that an invasive cardiologist back
then would make the decision to perform a highly complex PCI intervention in
a patient, but would rather send the patient for a MIDCAB. So this is the reason
I think we have to probably improve the validation of the results by excluding
the observational studies from the meta-analysis.
Dr D. Taggart (Oxford, UK): I believe the mean follow-up for these patients
was two years; is that correct?
Dr Deppe: Yes, that’s right. There was one study reporting the 10-year results,
but most of the studies stopped follow-up after 12 or 24 months.
Dr Taggart: I think this is very important in the interpretation of this data. If
we look at SYNTAX at ﬁve years for 3-vessel disease, there is a signiﬁcant sur-
vival advantage in patients with SYNTAX scores above 22. But if you look at
those same patients at 1, 2 or 3 years, there is no difference in survival. And it’s
only with further duration of follow-up that you begin to also see survival ad-
vantage of CABG.
So, for example, there are now 13 propensity-matched registries in the
literature containing 433,000 patients comparing CABG and PCI, and every one of
them shows a survival advantage from 5 to 7 percentage points at 5 years. But if
you look at those registry rates at 1, 2 or 3 years, there is no difference in survival.
And we have to get away from the mentality of nowmaking CABG an intervention
that we deﬁne with one- or two-year outcomes. That’s particularly so now when
you look at the evidence in the literature showing patency of mammary arteries
to the LAD of over 90% at 20 years of follow-up.
So we have to be very careful how we present this. Because this type of data
will be used by cardiologists to quote this paper and say, ‘Look, no difference
between CABG and PCI.’ And it’s long-term follow-up for the cardiologists
because it’s two years, so we have to be careful.
As we ﬁnish, I would like to ask the audience ‘Who believes that all patients
with proximal LAD disease should at least be discussed in terms of having a
mammary artery rather than just being stented?’ (Show of hands.) Oh, more
convincing. Then, let me ask you, ‘Who believes that patients with complex
disease of the proximal LAD should always be offered the beneﬁt of a discus-
sion about a mammary artery?’ (Show of hands.) Good. Thank you very much
for your presentation.
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Ischaemic lesions located in the proximal left anterior descending
(LAD) coronary artery are present in approximately 10% of
patients with stable coronary artery disease requiring myocardial
revascularization. In view of the associated prognostic beneﬁt, the
current joint guidelines of the European Society of Cardiology
(ESC) and the European Association for Cardio-Thoracic Surgery
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(EACTS) recommend myocardial revascularization with a Class I
and a level of evidence A for patients presenting with an isolated
>50% stenosis of the proximal LAD [1]. The optimal revasculariza-
tion strategy for these lesions, however, is still a matter of debate.
Surgical revascularization with minimally invasive direct coronary
artery bypass grafting (MIDCAB)—through a small left anterior
thoracotomy—has been developed to minimize surgical procedure
invasiveness and has effectively reduced the procedural complica-
tions associated with conventional coronary artery bypass surgery
(CABG) [2]. Alternatively, contemporary percutaneous coronary
interventions (PCIs) allow for a prompt revascularization procedure
with a catheter-based dilatation of the coronary stenosis optimized
by the implantation of a drug-eluting stent (DES) [3].
In this issue of the European Journal of Cardio-Thoracic Surgery,
Deppe et al. report the ﬁndings of a meta-analysis of 12 studies—in-
cluding a total of 2885 patients—directly comparing MIDCAB with
PCI for the treatment of isolated proximal LAD disease [4]. The
authors observed no signiﬁcant differences between the two revas-
cularization modalities with respect to mortality [odds ratio (OR)
0.98, 95% conﬁdence interval (CI) 0.70–1.39], cardiac mortality (OR
0.95, 95% CI 0.52–1.76), myocardial infarction (OR 1.05, 95% CI
0.71–1.56) and stroke (OR 1.22, 95% CI 0.60–2.48) during long-term
follow-up. However, PCI resulted to be associated with a shorter
length of hospital stay (weighted mean difference −3.37 days, 95%
CI −4.92 to −1.81 days) and a higher risk of target-vessel revasculari-
zation (OR 3.80, 95% CI 2.82–5.10) when compared with MIDCAB.
The ﬁndings of this meta-analysis need to be interpreted in
light of two important considerations. Firstly, Deppe et al. included
both randomized, controlled trials and observational studies in
their meta-analysis. This approach is methodologically debatable
as it may determine very precise but equally spurious results due
to confounders and selection bias [5]. Secondly, the authors
included any PCI strategy in the meta-analysis—ranging from plain
balloon angioplasty to DES implantation—despite signiﬁcant
changes in treatment effects have been consistently shown with
PCI technological evolution [3]. Contemporary PCI is based on the
implantation of DESs, which have signiﬁcantly improved safety
and efﬁcacy outcomes compared with bare metal stents or plain
balloon angioplasty [6, 7]. Therefore, pooling these different per-
cutaneous revascularization modalities in one single treatment
group does not adequately reﬂect contemporary clinical practice,
impairing the interpretability of the meta-analysis ﬁndings. As a
matter of fact, the signiﬁcant heterogeneity observed by the
authors for almost all the analysed outcomes is—at least in part—a
result of these two key limitations. It should also be emphasized
that adequate training and experience are key factors to achieve
high procedural success of MIDCAB, with patency rates of the LAD
anastomoses as high as those achieved with conventional CABG.
Keeping in mind these considerations, the ﬁndings of Deppe
et al. provide important information. The absence of any differ-
ences in the risks of mortality, myocardial infarction and stroke
between PCI and MIDCAB during long-term follow-up is a rele-
vant piece of evidence, which highlights that excellent minimally
invasive treatment options are available for patients with isolated
proximal LAD disease. As it relates to the risk of target-vessel
revascularization, the results are obviously biased by the mixture
of PCI modalities. The use of contemporary DESs has consistently
reduced the occurrence of restenosis and subsequent need for
repeat revascularization by over 80% when compared with bare
metal stents [8, 9]. In view of this well-established beneﬁt of DESs,
the authors’ ﬁndings with respect to target-vessel revascularization
should be interpreted with particular caution. As shown by the
authors in a sensitivity analysis, the risk of target-vessel revascular-
ization did not signiﬁcantly differ between PCI with DES com-
pared with MIDCAB (OR 3.50, 95% CI 0.98–12.52). Certainly, this
sensitivity analysis suffers from an imprecise point estimate with a
wide conﬁdence interval. In addition, the limited number and size
of randomized trials directly comparing DESs and MIDCAB does
not allow deﬁnitive conclusions. However, the available compara-
tive evidence is reassuring on the similar safety and efﬁcacy proﬁle
of PCI with DES and MIDCAB in patients with isolated proximal
LAD disease. This is reﬂected by the most recent joint guidelines on
myocardial revascularization of the ESC and EACTS that provide the
same class of recommendation (I) and level of evidence (A) for
both PCI with DESs and coronary artery bypass surgery for the
treatment of patients with isolated proximal LAD disease [1].
In summary, the ﬁndings of Deppe et al. show that surgical and
percutaneous minimally invasive treatment strategies can be
offered with excellent long-term clinical outcomes. Given that
myocardial revascularization is recommended in patients with iso-
lated proximal LAD lesions, the optimal treatment choice should
be based on patients’ preference, clinical and anatomical charac-
teristics, hospital and physician expertise and local Heart Team
protocols. Cardiovascular surgeons and interventional cardiolo-
gists should work in liaison in order to offer the best available min-
imally invasive treatment strategies since ‘no matter by what
various crafts we came here, but are all now in the same boat’ [10].
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